Allitinib tosylate (AST-1306) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). It is currently being studied as a potential treatment for various types of cancers, including non-small cell lung cancer and breast cancer. Allitinib tosylate was first developed by Ascentage Pharma and has undergone several clinical trials.
Chemical Name
The chemical name of Allitinib tosylate is 2-(3-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl)-1,1,1-trifluoro-3-tosylatepropan-2-ol.
Molecular Formula
The molecular formula of Allitinib tosylate is C30H28ClF3N3O7S.
Formula Weight
The formula weight of Allitinib tosylate is 661.07 g/mol.
CAS No.
The CAS number of Allitinib tosylate is 1050500-29-2.
Top Ten Keywords from Google and Synonyms
Synonyms: AST-1306, ASK-1306, 2-(3-{4-[3-chloro-2-(fluoromethyl)phenylamino]-7-methoxyquinazolin-6-yloxy}propyl)-1,1,1-trifluoro-3-tosylatepropan-2-ol
Health Benefits of Allitinib tosylate
Allitinib tosylate has shown promising results in treating various types of cancers, particularly non-small cell lung cancer and breast cancer. By inhibiting both EGFR and HER2, it works to slow or stop the growth and spread of cancer cells.
Potential Effects
Clinical studies have shown that Allitinib tosylate can effectively treat non-small cell lung cancer and breast cancer. In one phase II study, researchers found that Allitinib tosylate was well-tolerated and showed signs of efficacy in patients with advanced non-small cell lung cancer who had previously received other treatments.
Product Mechanism
Allitinib tosylate works by specifically targeting both EGFR and HER2, two proteins that are often overexpressed in cancer cells and play a critical role in regulating cell growth and survival. By inhibiting these proteins, Allitinib tosylate suppresses the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
Safety
Allitinib tosylate has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include diarrhea, nausea, vomiting, and fatigue. More severe side effects may occur in some patients, such as liver damage or allergic reactions. Patients should be closely monitored for any adverse reactions while taking Allitinib tosylate.
Side Effects
The most common side effects of Allitinib tosylate include:
More severe side effects may occur in some patients, such as:
Dosing Information
The dosing of Allitinib tosylate depends on the type of cancer being treated and other individual factors. It is typically administered orally in tablet form, either alone or in combination with other cancer therapies. The recommended dose varies depending on the clinical trial or physician's discretion.
Conclusion
In conclusion, Allitinib tosylate is a promising drug candidate for cancer therapy, particularly in the treatment of various types of cancers, including non-small cell lung cancer and breast cancer. As an inhibitor of both EGFR and HER2, it shows potential in suppressing the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression. While further clinical trials are needed to determine its efficacy and safety, Allitinib tosylate represents an important step towards precision medicine and molecular targeted therapy in cancer treatment
